David Sans, FAARM, PhD, MBA joined EF Hutton in December 2023 as Head of Healthcare, bringing with him many years of biotech and pharma experience in corporate finance, business development, operational, and commercial roles spanning both large pharmaceutical and emerging biotechnology companies. David oversees all Healthcare Transactions at EF Hutton spearheading and driving a wide range of industry transactions.

Previously, David served as Head of Market Analytics at Pfizer during the launch of Rebif® (interferon beta-1a for MS) and Macugen® (pegaptanib) and as Sr. Medical Scientist at Novartis in Basel, Switzerland during the launch of Glivec® (imatinib), at ImClone Systems and Head of Corporate Development and David served as an Executive Officer at Mount Sinai Health Systems completing Business Development transactions with Philips, LabCorp, and Agilent. David is also a Board Member of the Lymphatic Education & Research Network in New York.

Dr. Sans holds a Ph.D. in Chemical Engineering from University Ramon Lull in collaboration with the ETH in Zürich, an MBA in Business Law from Fordham in NYC, and he is the recipient of the Don Sheehan International Scholarship to the Wharton School of Business in Philadelphia. David holds a Fellowship in Anti-Aging and Regenerative Medicine from the American Academy and Board of Regenerative Medicine and passed FINRA exams including Series 7, 63, 79, 17 and 55.